Summary of demographic and clinical data.

ON, optic neuritis;*, relapses treated with high dose steroid pulse therapy; no included patient had an ON within 12 months prior to the beginning of the study; GLAT, glatiramer-acetate 20 mg subcutaneous once daily; MITOX, mitoxantrone; IFN(a), interferon beta 1a intramuscularly once per week; IFN(b), interferon beta 1a (44 µg) subcutaneous trice per week; IFN(c), interferon beta 1b (250 µg) subcutaneous alternate day;1, discontinued (48 mg mitoxantrone per m2 body surface); none, neither specific immunomodulatory or immunsuppressive therapy, drug holiday;2, drug withdrawal 9 months after 1st OCT examination;3, start 7 months before 2nd OCT examination;4, drug withdrawal 12 months before 1st OCT examination;5, drug withdrawal 6 months before 1st OCT examination;6, drug withdrawal 20 months before 1st OCT examination;7, strict vegan diet caused vitamin B12 and folate deficiency;8, high titres of anti-interferon autoantibodies, drug withdrawal 14 months before 1st OCT examination;9, drug withdrawal 25 months before 1st OCT examination;10, drug withdrawal 8 months before 1st OCT examination;11, mitoxantrone cumulative dose 96 mg per m2 body surface, drug withdrawal 10 months before 1st OCT examination;12, change to natalizumab 2 months after 1st OCT examination;13, drug withdrawal 6 months before 1st OCT examination;14, mitoxantrone cumulative dose 92 mg per m2 body surface, drug withdrawal 10 months before 1st OCT examination;15, mitoxantrone cumulative dose 92 mg per m2 body surface, drug withdrawal 26 months before 1st OCT examination;16, drug withdrawal 5 months after 1st OCT examination.17, mitoxantrone cumulative dose 108 mg per m2 body surface, drug withdrawal 27 months before 1st OCT examination;